Abstract
Osteogenesis imperfecta (OI) is a heritable disorder, in both a dominant and recessive manner, of connective tissue characterized by brittle bones, fractures and extraskeletal manifestations1. How structural mutations of type I collagen (dominant OI) or of its post-translational modification machinery (recessive OI) can cause abnormal quality and quantity of bone is poorly understood. Notably, the clinical overlap between dominant and recessive forms of OI suggests common molecular pathomechanisms2. Here, we show that excessive transforming growth factor-β (TGF-β) signaling is a mechanism of OI in both recessive (Crtap−/−) and dominant (Col1a2tm1.1Mcbr) OI mouse models. In the skeleton, we find higher expression of TGF-β target genes, higher ratio of phosphorylated Smad2 to total Smad2 protein and higher in vivo Smad2 reporter activity. Moreover, the type I collagen of Crtap−/− mice shows reduced binding to the small leucine-rich proteoglycan decorin, a known regulator of TGF-β activity3,4. Anti–TGF-β treatment using the neutralizing antibody 1D11 corrects the bone phenotype in both forms of OI and improves the lung abnormalities in Crtap−/− mice. Hence, altered TGF-β matrix-cell signaling is a primary mechanism in the pathogenesis of OI and could be a promising target for the treatment of OI.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rauch, F. & Glorieux, F.H. Osteogenesis imperfecta. Lancet 363, 1377–1385 (2004).
Baldridge, D. et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum. Mutat. 29, 1435–1442 (2008).
Markmann, A., Hausser, H., Schonherr, E. & Kresse, H. Influence of decorin expression on transforming growth factor-β–mediated collagen gel retraction and biglycan induction. Matrix Biol. 19, 631–636 (2000).
Takeuchi, Y., Kodama, Y. & Matsumoto, T. Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J. Biol. Chem. 269, 32634–32638 (1994).
Morello, R. et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 127, 291–304 (2006).
Mizuno, K., Peyton, D.H., Hayashi, T., Engel, J. & Bächinger, H.P. Effect of the -Gly-3(S)-hydroxyprolyl-4(R)-hydroxyprolyl- tripeptide unit on the stability of collagen model peptides. FEBS J. 275, 5830–5840 (2008).
Homan, E.P. et al. Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues. PLoS Genet. 10, e1004121 (2014).
Tang, Y. et al. TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757–765 (2009).
Yang, T. et al. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment. Proc. Natl. Acad. Sci. USA 110, 7336–7341 (2013).
Dallas, S.L. et al. Characterization and autoregulation of latent transforming growth factor β (TGF β) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF β–binding protein. J. Biol. Chem. 269, 6815–6821 (1994).
Hering, S. et al. TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples. Exp. Clin. Endocrinol. Diabetes 109, 217–226 (2001).
Oreffo, R.O., Mundy, G.R., Seyedin, S.M. & Bonewald, L.F. Activation of the bone-derived latent TGF β complex by isolated osteoclasts. Biochem. Biophys. Res. Commun. 158, 817–823 (1989).
Hildebrand, A. et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J. 302, 527–534 (1994).
Erlebacher, A. & Derynck, R. Increased expression of TGF-β 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132, 195–210 (1996).
Neptune, E.R. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407–411 (2003).
Baldridge, D. et al. Generalized connective tissue disease in Crtap−/− mouse. PLoS ONE 5, e10560 (2010).
Thiele, F. et al. Cardiopulmonary dysfunction in the osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms. Hum. Mol. Genet. 21, 3535–3545 (2012).
McAllion, S.J. & Paterson, C.R. Causes of death in osteogenesis imperfecta. J. Clin. Pathol. 49, 627–630 (1996).
Rauch, F., Travers, R., Parfitt, A.M. & Glorieux, F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26, 581–589 (2000).
Ward, L.M. et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31, 12–18 (2002).
Janssens, K., ten Dijke, P., Janssens, S. & Van Hul, W. Transforming growth factor-β1 to the bone. Endocr. Rev. 26, 743–774 (2005).
Fuller, K., Lean, J.M., Bayley, K.E., Wani, M.R. & Chambers, T.J. A role for TGFβ1 in osteoclast differentiation and survival. J. Cell Sci. 113, 2445–2453 (2000).
Xian, L. et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095–1101 (2012).
Alliston, T., Choy, L., Ducy, P., Karsenty, G. & Derynck, R. TGF-β–induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20, 2254–2272 (2001).
Edwards, J.R. et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J. Bone Miner. Res. 25, 2419–2426 (2010).
Sarathchandra, P., Pope, F.M., Kayser, M.V. & Ali, S.Y. A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype. J. Pathol. 192, 385–395 (2000).
Karsdal, M.A. et al. Matrix metalloproteinase–dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277, 44061–44067 (2002).
Gauldie, J. et al. Transfer of the active form of transforming growth factor-β 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am. J. Pathol. 163, 2575–2584 (2003).
Morty, R.E., Konigshoff, M. & Eickelberg, O. Transforming growth factor-β signaling across ages: from distorted lung development to chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6, 607–613 (2009).
Marwick, J.A. et al. Cigarette smoke-induced oxidative stress and TGF-β1 increase p21waf1/cip1 expression in alveolar epithelial cells. Ann. NY Acad. Sci. 973, 278–283 (2002).
Hausser, H., Groning, A., Hasilik, A., Schonherr, E. & Kresse, H. Selective inactivity of TGF-β/decorin complexes. FEBS Lett. 353, 243–245 (1994).
Keene, D.R. et al. Decorin binds near the C terminus of type I collagen. J. Biol. Chem. 275, 21801–21804 (2000).
Marini, J.C. et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 28, 209–221 (2007).
Schönherr, E. et al. Interaction of biglycan with type I collagen. J. Biol. Chem. 270, 2776–2783 (1995).
Nikitovic, D. et al. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 287, 33926–33933 (2012).
Christ, M. et al. Immune dysregulation in TGF-β 1–deficient mice. J. Immunol. 153, 1936–1946 (1994).
Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236–1243 (2011).
Lonning, S., Mannick, J. & McPherson, J.M. Antibody targeting of TGF-β in cancer patients. Curr. Pharm. Biotechnol. 12, 2176–2189 (2011).
Morris, J.C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-β (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 11, e90353 (2014).
Orwoll, E.S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Invest. 124, 491–498 (2014).
Daley, E. et al. Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model. J. Bone Miner. Res. 25, 247–261 (2010).
Lin, A.H. et al. Global analysis of Smad2/3-dependent TGF-β signaling in living mice reveals prominent tissue-specific responses to injury. J. Immunol. 175, 547–554 (2005).
Abe, M. et al. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276–284 (1994).
Chen, Z.H. et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc. Natl. Acad. Sci. USA 107, 18880–18885 (2010).
Eyre, D. Collagen cross-linking amino acids. Methods Enzymol. 144, 115–139 (1987).
Acknowledgements
We thank D. Spencer and his lab (Baylor College of Medicine) for providing the IVIS camera system and training, M. Starbuck and F. Gannon for consultation and advice in bone histomorphometry, M. Warman and C. Jacobsen (Boston Children's Hospital) for providing the Col1a2tm1.1Mcbr mice and helpful information. We also thank L. Fisher (US National Institute of Dental and Craniofacial Research) for providing the decorin antibody LF-113. We thank M. Bagos for help with microCT analyses, A. Abraham for help with the biomechanical testing, W. Song and S. Liu for their help with serum bone turnover analyses, the US National Institutes of Health (NIH) for providing the ImageJ software and A. Choi and H. Lam (Harvard Medical School) for providing the ImageJ modification for lung morphometry, which was generated by P. Thompson. Also, we thank D. Rifkin (New York University Medical Center) for providing PAI-luciferase reporter mink lung epithelial cells. In addition, we thank R. Morello, G. Sule, D. Baldridge and G. Ghosal for their helpful discussions and P. Fonseca for editorial assistance. This work was supported by a research fellowship from the German Research Foundation/Deutsche Forschungsgemeinschaft (I.G.), a Michael Geisman Fellowship from the Osteogenesis Imperfecta Foundation (I.G.), grant support from Shriners Hospitals for Children (H.P.B.), NIH grants 5F31DE020954 (E.P.H.), 5F31DE022483 (C.L.), R37 AR037318 and R01 AR036794 (D.E.), and P01 HD70394 (B.L. and D.E.) and the Howard Hughes Medical Institute Foundation (B.L.). This work was also supported by the Baylor College of Medicine Intellectual and Developmental Disabilities Research Center (HD024064), the Eunice Kennedy Shriver US National Institute of Child Health & Human Development and the Rolanette and Berdon Lawrence Bone Disease Program of Texas.
Author information
Authors and Affiliations
Contributions
I.G. and B.L. conceptualized the study. T.Y., T.K.S., C.A., D.E. and H.P.B. contributed to the design of the study and experiments. I.G., T.Y., S.A., E.P.H., C.L., M.M.J., T.B., E.M., Y.C., B.D., Y.I., M.A.W. and C.A. performed and analyzed experiments. I.G., T.Y. and B.L. wrote the manuscript with contributions from all authors. B.L. supervised the project.
Corresponding author
Ethics declarations
Competing interests
T.K.S. is an employee of Genzyme/Sanofi.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 and Supplementary Tables 1–6. (PDF 6884 kb)
Rights and permissions
About this article
Cite this article
Grafe, I., Yang, T., Alexander, S. et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med 20, 670–675 (2014). https://doi.org/10.1038/nm.3544
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3544
This article is cited by
-
The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease
Cell Research (2024)
-
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta
Calcified Tissue International (2024)
-
Targeting strategies for bone diseases: signaling pathways and clinical studies
Signal Transduction and Targeted Therapy (2023)
-
Standardized growth charts for children with osteogenesis imperfecta
Pediatric Research (2023)
-
The Multifaceted Effects of Osteocytic TGFβ Signaling on the Skeletal and Extraskeletal Functions of Bone
Current Osteoporosis Reports (2023)